Biblio

12 resultats trouvés
Filtres: Mot-clé is Venous thromboembolism  [Clear All Filters]
2
, Meyer G, Becattini C, Bueno H, Geersing G-J, Harjola V-P, , Humbert M, Jennings CSian, Jimenez D et al..  2020.  2019 ESC Guidelines for the dignosis and management of acute pulmonary embolism development Toed in colaboration with the European Respiratory Society (ERS). EUROPEAN HEART JOURNAL. 41:543-603.
C
Le Guenno G, Guieze R, Audia S, Khellaf M, Michel M, Bonnotte B, Ruivard M, Godeau B.  2019.  Characteristics, risk factors and management of venous thromboembolism in immune thrombocytopenia: a retrospective multicentre study. INTERNAL MEDICINE JOURNAL. 49:1154-1162.
Howlett J, Benzenine E, Jonathan C, Foucher P, Fagnoni P, Quantin C.  2020.  Could venous thromboembolism and major bleeding be indicators of lung cancer mortality? A nationwide database study BMC CANCER. 20
E
van Es N, Di Nisio M, Bleker SM, Segers A, Mercuri MF, Schwocho L, Kakkar A, Weitz JI, Beyer-Westendorf J, Boda Z et al..  2015.  Edoxaban for treatment of venous thromboembolism in patients with cancer Rationale and design of the Hokusai VTE-cancer study. THROMBOSIS AND HAEMOSTASIS. 114:1268-1276.
F
Debourdeau P., Arvers P., Hij A., Bennani H., Desauw C., Falvo N., Ghiringhelli F., Hamade A., Vedrine L., Farge D..  2020.  Factors influencing patient's perception of long-term treatment with low-molecular-weight heparins for cancer-associated thrombosis: an updated analysis of TROPIQUE, a prospective observational study. SUPPORTIVE CARE IN CANCER. 28:287-293.
Girard P, Laporte S, Chapelle C, Falvo N, Falchero L, Cloarec N, Monnet I, Burnod A, Tomasini P, Boulon C et al..  2022.  Failure of the Ottawa Score to Predict the Risk of Recurrent Venous Thromboembolism in Cancer Patients: The Prospective PREDICARE Cohort Study. THROMBOSIS AND HAEMOSTASIS. 122:151-157.
H
Allaert F-A, Benzenine E, Quantin C.  2017.  Hospital incidence and annual rates of hospitalization for venous thromboembolic disease in France and the USA. PHLEBOLOGY. 32:443-447.
I
Duan Q, Wang L, Yang F, Li J, Song Y, Gong Z, Li G, Song H, Zhang X, Shen Z et al..  2015.  Internal relationship between symptomatic venous thromboembolism and risk factors: up-regulation of integrin beta 1, beta 2 and beta 3 levels. AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH. 7:624-631.
K
Ramos JD, Casey MF, Bamias A, De Giorgi U, Bellmunt J, Harshman LC, Ladoire S, Wong Y-N, Alva AS, Rosenberg JE et al..  2017.  The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS. 23:755-760.
M
Allaert F-A, Benzenine E, Quantin C.  2016.  More than one in two venous thromboembolism treated in French hospitals occurs during the hospital stays. PHLEBOLOGY. 31:390-396.
T
Lim MY, Deal AM, Kim S, Musty MD, Conard J, Simioni P, Dutrillaux F, Eid SS, Middeldorp S, Halbmayer WM et al..  2016.  Thrombophilic risk of individuals with rare compound factor V Leiden and prothrombin G20210A polymorphisms: an international case series of 100 individuals. EUROPEAN JOURNAL OF HAEMATOLOGY. 97:353-360.
V
Ramos JD, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong Y-N, Bellmunt J, De Giorgi U, Ladoire S, Powles T et al..  2017.  Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival. CANCER MEDICINE. 6:186-194.